Luminous JV Lands Full-Building San Diego Industrial Lease
A manufacturer will occupy the 75,000-square-foot asset.
Luminous Capital Management, in partnership with Virtus Real Estate Capital, has signed Reotemp Instrument Corp. to the entirety of 10225 Willow Creek Road, a 75,000-square-foot industrial asset in San Diego’s Scripps Ranch submarket.
Reotemp, a manufacturer of temperature and pressure instrumentation, will move in upon completion of its buildout, which is slated for the second quarter of 2027.
The company will consolidate several locations that it occupies in Sorrento Valley and expand its California operations from about 35,000 square feet to 55,000 square feet. The remainder of 10225 Willow Creek Road will provide Reotemp with built-in space for future growth.
READ ALSO: How Top CRE Brokers Hone Their Reputations
The property will house Reotemp’s headquarters, including executive, sales and marketing, and administrative functions. The San Diego facility will also perform R&D, engineering, manufacturing, distribution and customer service operations for some of the company’s products. Additional Reotemp operations are at a second plant in Houston.
Luminous and Virtus acquired the Scripps Ranch property in 2021 from its former occupant, LG Electronics USA, and then conducted extensive renovations. The partnership’s repositioning increased the building’s electrical power to 4,000 amps in order to better target life sciences users and other advanced manufacturing operations.
Cushman & Wakefield’s San Diego office represented both landlord and tenant in the deal. Vice Chairs Brant Aberg and Louay Alsadek, along with Vice Chairman Bryce Aberg, represented Luminous in marketing the property, while Managing Director Andy Ewald and Executive Director Peter Curry represented Reotemp. Cushman & Wakefield’s Project Development Services team, led by Managing Director Jason Thatcher, is overseeing the tenant improvements.
Manufacturing Sector Sees Growth
U.S. manufacturing was up significantly in 2025 from the year before, according to a Savills report, especially in terms of new major commitments, but the sector isn’t enjoying the heights seen in 2022. Between November 2024 and November 2025, 53,416 manufacturing jobs were announced, up from the previous year’s total of 30,853.
Some recent investments in the sector are enormous, such as Johnson & Johnson investing $1 billion in a cell therapy manufacturing facility in Lower Gwynedd Township, Pa. The facility will produce cell therapy treatments for cancer, immune-mediated and other diseases, and will be open by 2031.
In another pharma deal late last year, Eli Lilly and Co. picked Huntsville, Ala., as the site of a $6 billion manufacturing facility. Construction is expected to be completed by 2032.
You must be logged in to post a comment.